Loading
Eton Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Jun 2025.
Eton Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Eton Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Eton Pharmaceuticals, Inc. logged 53 filings by 12 insiders.
All open-market trades in the period are sales: 24 sales worth €20.5M, by 5 insiders, with no purchase on record. No amount is published for 1 filing, which the totals therefore leave out. Brynjelsen Sean filed the largest sale, €3.3M, on 29 May 2026, which represents 0.21% of the company's market value.
Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 53 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. The full history, which starts in 2021, counts 8 purchases against 35 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 80.0 m USD and net income at -4.6 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
73
Thresholds
n/a
Buy Volume
€548,115
8 ops. · all time
Sell Volume
€25M
35 ops. · all time
Who traded when
BuySaleOpaleye Management Inc.1 buy9 sales
David Krempa8 sales
Sean Brynjelsen7 sales
Paul Maier V6 sales
Adams Jennifer McKie1 sale
Gruber James R.1 sale
Since the insiders bought
- +124.8%Entry US$14.30 · Close at T+365 US$32.15
- +130.4%Entry US$2.04 · Close at T+365 US$4.70
- -51.6%Entry US$4.81 · Close at T+365 US$2.33
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Eton Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$71.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,657 of 24,148 companies
42.1
score / 100
Value36
Quality48
FCF yld0.7%
Earn yld-0.3%
EV/EBITDA·
ROE36%
Gross mgn53%
Net mgn-5.8%
Debt/EBITDA9.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$52.88
Analyst consensus
4 analystsStrong buy
US$68.00Target US$71.00(+34%)US$76.00
Income statement
RevenueUS$80M
Gross profitUS$42.7M53% margin
EBITDAUS$3.2M4% margin
Net income-US$4.6M12.0% margin
Valuation
PER (trailing)132.2x
PER (forward)20.5x
P/Book32.1x
Beta0.90
Balance sheet & cash
Market capUS$1.5B
Total debtUS$31M
Free Cash FlowUS$10.2M
Debt / Equity63%
Profitability & ownership
ROE36.0%
ROA11.9%
% insiders4.9%
% institutions71.4%
Last declaration on 6 October 2026
Declarations73 total
4,166 shares@ US$55.06630.014% mcap4.1% of flowCommon StockSEC:0001437749-26-032240:1
10,522 sharesCommon StockSEC:0001437749-26-032240:0
12,500 shares@ US$7.310.0056% mcap1.5% of flowCommon StockSEC:0001437749-26-029308:4
50,000 shares@ US$59.07060.18% mcap47.7% of flowCommonSEC144:0001974078-26-000335
50,000 shares@ US$3.780.012% mcap3.1% of flowCommon StockSEC:0001437749-26-029196:0
36,387 shares@ US$58.640.13% mcap34.5% of flowCommon StockSEC:0001437749-26-029196:1
13,485 shares@ US$60.210.050% mcap13.1% of flowCommon StockSEC:0001437749-26-029196:2
128 shares@ US$61.770.0005% mcap0.1% of flowCommon StockSEC:0001437749-26-029196:3
25,000 shares@ US$7.310.011% mcap3.2% of flowCommon StockSEC:0001437749-26-028846:0
25,000 shares@ US$65.070.100% mcap28.8% of flowCommon StockSEC:0001437749-26-028846:1
8,978 shares@ US$62.650.035% mcap3.2% of flowCommon StockSEC:0001437749-26-028651:0
47,307 shares@ US$60.170.17% mcap15.8% of flowCommon StockSEC:0001437749-26-028651:1
36,373 shares@ US$61.110.14% mcap12.4% of flowCommon StockSEC:0001437749-26-028651:2
7,342 shares@ US$62.120.028% mcap2.5% of flowCommon StockSEC:0001437749-26-028651:3
100,000 shares@ US$63.430.39% mcap35.6% of flowCommonSEC144:0001974078-26-000315
15,000 shares@ US$37.54310.035% mcap5.6% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033577:0
13,315 shares@ US$37.54310.031% mcap5.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-033577:1
27,500 sharesCommon StockSEC:0001437749-26-023570:0
200,000 shares@ US$1.370.017% mcap1.6% of flowCommon StockSEC:0001437749-26-023570:1
10,000 sharesCommon StockSEC:0001437749-26-023440:0
65,000 shares@ US$37.38510.15% mcap24.1% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-032394:0
25,000 shares@ US$37.38510.059% mcap9.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-032394:1
10,000 shares@ US$38.000.024% mcap3.8% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-032394:2
20,000 shares@ US$38.37280.048% mcap7.6% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-032394:3
6,685 shares@ US$38.37280.016% mcap2.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-032394:4
25 of 73 declarations
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ticker: ETON) is a U.S.-listed specialty pharmaceutical company traded on the NASDAQ in the United States. Headquartered in Deer Park, Illinois, Eton was incorporated in 2017 as a separate entity emerging from the Imprimis/Harrow Health ecosystem, and it originally focused on hospital injectables and rare-disease therapies. Its business model is built around acquiring, developing, and commercializing niche prescription products, often using the FDA 505(b)(2) pathway to bring differentiated therapies to market faster than a traditional de novo development program. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710340/000161577418012575/s114004_424b4.htm?utm_source=openai))
Today, Eton positions itself as a rare-disease and ultra-rare-disease company with a portfolio that combines marketed products, licensing revenue, and late-stage development assets. The company’s marketed products include ALKINDI SPRINKLE, INCRELEX, KHINDIVI, HEMANGEOL, GALZIN, CARGLUMIC ACID, BETAINE, NITISINONE CAPSULES, PKU GOLIKE, and TYR GOLIKE. This breadth gives Eton a commercial base while also supporting a pipeline-driven growth story. The company’s revenue mix is therefore more diversified than that of a pure R&D biotech, but still concentrated in a relatively small set of specialty products. ([etonpharma.com](https://www.etonpharma.com/products/))
Read moreShow less
From a competitive standpoint, Eton is a small-cap specialist rather than a broad-based pharma platform. Its advantage lies in focus, regulatory agility, and the ability to identify under-served markets where a new formulation, a relaunch, or a rights acquisition can create value. At the same time, the company faces the typical risks of a niche pharmaceutical business: dependence on a limited number of products, regulatory timing risk, commercial execution risk, and pricing/reimbursement pressure. Eton’s current strategy reflects a blend of product acquisition, in-house development, and selective out-licensing, aimed at building a durable rare-disease franchise. ([etonpharma.com](https://www.etonpharma.com/products/))
Recent developments suggest meaningful momentum. In 2025, Eton reported continued sequential growth in product sales, moved GALZIN into its own commercial distribution infrastructure, submitted an NDA for ET-600, and out-licensed ex-U.S. rights to INCRELEX to Esteve Pharmaceuticals. The company also highlighted several expected product launches and additional late-stage programs. Its latest annual report confirms the company remains based in Deer Park, Illinois, and notes that Medicare exposure is limited because only a small portion of Eton’s products are prescribed to Medicare patients. For French, Belgian, and Swiss investors, ETON is therefore best viewed as a NASDAQ-listed United States specialty pharma company with a rare-disease focus, a modest commercial footprint, and a pipeline geared toward high-value niche indications. ([ir.etonpharma.com](https://ir.etonpharma.com/static-files/8bea9cbb-49a6-4242-8f74-af05c5036636))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
